Department of Physiology, Shiga University of Medical Science, Otsu, Shiga, Japan; and.
Department of Anesthesiology, Shiga University of Medical Science, Otsu, Shiga, Japan.
J Cardiovasc Pharmacol. 2021 Dec 1;78(6):826-838. doi: 10.1097/FJC.0000000000001133.
Dexmedetomidine (DEX), an α2-adrenoreceptor (α2-AR) and imidazoline receptor agonist, is most often used for the sedation of patients in the intensive care unit. Its administration is associated with an increased incidence of bradycardia; however, the precise mechanism of DEX-induced bradycardia has yet to be fully elucidated. This study was undertaken to examine whether DEX modifies pacemaker activity and the underlying ionic channel function through α2-AR and imidazoline receptors. The whole-cell patch-clamp techniques were used to record action potentials and related ionic currents of sinoatrial node cells in guinea pigs. DEX (≥10 nM) reduced sinoatrial node automaticity and the diastolic depolarization rate. DEX reduced the amplitude of hyperpolarization-activated cation current (If or Ih) the pacemaker current, even within the physiological pacemaker potential range. DEX slowed the If current activation kinetics and caused a significant shift in the voltage dependence of channel activation to negative potentials. In addition, efaroxan, an α2-AR and imidazoline I1 receptor antagonist, attenuated the inhibitory effects of DEX on sinoatrial node automaticity and If current activity, whereas yohimbine, an α2-AR-selective antagonist, did not. DEX did not affect the current activities of other channels, including rapidly and slowly activating delayed rectifier K+ currents (IKr and IKs), L-type Ca2+ current (ICa,L), Na+/Ca2+ exchange current (INCX), and muscarinic K+ current (IK,ACh). Our results indicate that DEX, at clinically relevant concentrations, induced a negative chronotropic effect on the sinoatrial node function through the downregulation of If current through an imidazoline I1 receptor other than the α2-AR in the clinical setting.
右美托咪定(DEX)是一种 α2-肾上腺素受体(α2-AR)和咪唑啉受体激动剂,最常用于重症监护病房患者的镇静。其给药与心动过缓的发生率增加有关;然而,DEX 诱导心动过缓的确切机制尚未完全阐明。本研究旨在探讨 DEX 是否通过 α2-AR 和咪唑啉受体改变起博活性和潜在的离子通道功能。采用全细胞膜片钳技术记录豚鼠窦房结细胞的动作电位和相关离子电流。DEX(≥10 nM)降低窦房结自动性和舒张去极化率。DEX 降低了超极化激活阳离子电流(If 或 Ih)起搏电流的幅度,即使在生理起搏电位范围内也是如此。DEX 减缓了 If 电流激活动力学,并导致通道激活的电压依赖性向负电位显著转移。此外,α2-AR 和咪唑啉 I1 受体拮抗剂依氟烷减弱了 DEX 对窦房结自动性和 If 电流活动的抑制作用,而 α2-AR 选择性拮抗剂育亨宾则没有。DEX 不影响其他通道的电流活动,包括快速和缓慢激活的延迟整流钾电流(IKr 和 IKs)、L 型钙电流(ICa,L)、Na+/Ca2+交换电流(INCX)和毒蕈碱 K+电流(IK,Ach)。我们的结果表明,DEX 在临床相关浓度下通过下调临床环境中除 α2-AR 以外的咪唑啉 I1 受体的 If 电流,对窦房结功能产生负性变时作用。